The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practicePaula I. González-Ericsson|The Journal of Pathology|2020Cited by 223
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisSusana García‐Recio, Lisa A. Carey, Toshinori Hinoue et al.|Nature Cancer|2022Cited by 114
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLCPortia Thomas, Christine M. Lovly, Shamilene Sivagnanam et al.|Journal of Thoracic Oncology|2021Cited by 33